A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-31001074 compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Criteria

Inclusion Criteria:

• Diagnosis of attention deficit hyperactivity disorder with symptoms from age 7

• In good general health

• Willing to not take any other ADHD medication or start any behaviorial modification programs during the study

• Willing to use approved birth control throughout the study and for 3 months afterwards

Exclusion Criteria:

• Any psychiatric condition including acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), anti-social personality disorder or borderline personality disorder

• Autism, asperger's syndrome, mental retardation

• Presence of motor tics, history of Tourette's syndrome or family history of Tourette's syndrome

• History of substance use/abuse disorder or eating disorder

• History of myocardial infarction, stroke, glaucoma, seizures, hypertension, heart rhythm abnormalities or color blindness

• Use of prescription medication or herbal supplements